Literature DB >> 29126110

Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management.

Angela Cano1, Belén Gutiérrez-Gutiérrez2,3, Isabel Machuca1, Irene Gracia-Ahufinger4, Elena Pérez-Nadales5, Manuel Causse4, Juan José Castón1, Julia Guzman-Puche4, Julian Torre-Giménez1, Lara Kindelán1, Luis Martínez-Martinez4, Jesús Rodriguez-Baño2,3, Julian Torre-Cisneros1.   

Abstract

Background: The management and indication of empiric treatment in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp)-colonized patients should be improved.
Methods: A prospective cohort of 94 patients colonized by KPC-Kp was followed for 90 days to validate (i) the Giannella risk score (GRS) to predict the development of any type of KPC-Kp infection and (ii) the INCREMENT-CPE score (ICS) to predict 30-day mortality in patients with infection. Both scores were combined to recommend appropriate empiric treatment. The predictive ability of the scores was measured by calculating the area under the receiver operating characteristic (AUROC) curve.
Results: The GRS showed an AUROC curve for infection due to KPC-Kp of 0.92 (95% confidence interval [CI], .87-.98). The optimal cutoff point was fixed at <7 and ≥7 (92.9% sensitivity, 84.8% specificity); infection developed in 6.3% patients in the 0-6 GRS group and in 84.8% patient in the ≥7 GRS group. According to the ICS, the severity of the infection was also significantly higher in the ≥7 GRS group. The ICS showed an AUROC of 0.78 (95% CI, .65-.91) for 30-day all-cause mortality among patients with infection. A classification and regression tree analysis confirmed the GRS cutoff point at 7, and selected ≥12 points to predict a KPC-Kp infection with a high ICS. Conclusions: Our results validate the GRS and ICS for indicating empiric therapy in KPC-Kp-colonized patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29126110     DOI: 10.1093/cid/cix991

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  A multidrug-resistant microorganism infection risk prediction model: development and validation in an emergency medicine population.

Authors:  Juan González Del Castillo; Agustín Julián-Jiménez; Julio Javier Gamazo-Del Rio; Eric Jorge García-Lamberechts; Ferrán Llopis-Roca; Josep María Guardiola Tey; Mikel Martínez-Ortiz de Zarate; Carmen Navarro Bustos; Pascual Piñera Salmerón; Jesús Álvarez-Manzanares; María Del Mar Ortega Romero; Martin Ruiz Grinspan; Susana García Gutiérrez; Francisco Javier Martín-Sánchez; Francisco Javier Candel González
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-13       Impact factor: 3.267

2.  Successful treatment of Verona integron-encoded metallo-β-lactamase-producing Klebsiella pneumoniae infection using the combination of ceftazidime/avibactam and aztreonam.

Authors:  Ana Pelaez Bejarano; Raquel Sánchez-Del Moral; Olalla Montero-Pérez; Francisco Javier Martínez-Marcos
Journal:  Eur J Hosp Pharm       Date:  2021-10-29

3.  Impact of KPC Production and High-Level Meropenem Resistance on All-Cause Mortality of Ventilator-Associated Pneumonia in Association with Klebsiella pneumoniae.

Authors:  Francisco Rivera-Espinar; Isabel Machuca; Rocio Tejero; Jorge Rodríguez; Ana Mula; Eduardo Marfil; Ángela Cano; Belén Gutiérrez-Gutiérrez; Marina Rodríguez; Juan Carlos Pozo; Carmen De la Fuente; Jesús Rodriguez-Baño; Luis Martínez-Martínez; Rafael León; Julian Torre-Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

4.  Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae: A Single-Center, Observational Study.

Authors:  F Cancelli; A Oliva; M De Angelis; M T Mascellino; C M Mastroianni; V Vullo
Journal:  Biomed Res Int       Date:  2018-11-18       Impact factor: 3.411

5.  Tracking Carbapenem-Producing Klebsiella pneumoniae Outbreak in an Intensive Care Unit by Whole Genome Sequencing.

Authors:  Chen Chen; Yi Zhang; Sheng-Lei Yu; Yang Zhou; Si-Yu Yang; Jia-Lin Jin; Shu Chen; Peng Cui; Jing Wu; Ning Jiang; Wen-Hong Zhang
Journal:  Front Cell Infect Microbiol       Date:  2019-08-08       Impact factor: 5.293

Review 6.  Machine Learning and Multidrug-Resistant Gram-Negative Bacteria: An Interesting Combination for Current and Future Research.

Authors:  Daniele Roberto Giacobbe; Sara Mora; Mauro Giacomini; Matteo Bassetti
Journal:  Antibiotics (Basel)       Date:  2020-01-31

7.  Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam.

Authors:  Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Sahil Bhatia; Sarah M Melvin; Samuel P Simon; Joshua R Rosenberg; Molly E Steed; Sandra J Estrada; Taylor Morrisette; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2020-02-22

8.  Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.

Authors:  Oliver A Cornely; José M Cisneros; Julian Torre-Cisneros; María Jesús Rodríguez-Hernández; Luis Tallón-Aguilar; Esther Calbo; Juan P Horcajada; Christian Queckenberg; Ulrike Zettelmeyer; Dorothee Arenz; Clara M Rosso-Fernández; Silvia Jiménez-Jorge; Guy Turner; Susan Raber; Seamus O'Brien; Alison Luckey
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.790

Review 9.  How to manage KPC infections.

Authors:  Matteo Bassetti; Maddalena Peghin
Journal:  Ther Adv Infect Dis       Date:  2020-05-14

10.  Colonization Dynamics of Multidrug-Resistant Klebsiella pneumoniae Are Dictated by Microbiota-Cluster Group Behavior over Individual Antibiotic Susceptibility: A Metataxonomic Analysis.

Authors:  János Juhász; Balázs Ligeti; Márió Gajdács; Nóra Makra; Eszter Ostorházi; Ferenc Balázs Farkas; Balázs Stercz; Ákos Tóth; Judit Domokos; Sándor Pongor; Dóra Szabó
Journal:  Antibiotics (Basel)       Date:  2021-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.